Trial Profile
Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 10 Aug 2020 Results assessing the efficacy and tolerability of sorafenib maintenance post-transplantation published in the Lancet Oncology
- 21 Jun 2020 Primary endpoint has been met. (Incidence of leukemia relapse)
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association